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Abstract
Background: Small insertions and deletions (indels) have a significant influence in human disease and, in terms of
frequency, they are second only to single nucleotide variants as pathogenic mutations. As the majority of mutations
associated with complex traits are located outside the exome, it is crucial to investigate the potential pathogenic
impact of indels in non-coding regions of the human genome.
Results: We present FATHMM-indel, an integrative approach to predict the functional effect, pathogenic or neutral,
of indels in non-coding regions of the human genome. Our method exploits various genomic annotations in addition
to sequence data. When validated on benchmark data, FATHMM-indel significantly outperforms CADD and GAVIN,
state of the art models in assessing the pathogenic impact of non-coding variants. FATHMM-indel is available via a
web server at indels.biocompute.org.uk.
Conclusions: FATHMM-indel can accurately predict the functional impact and prioritise small indels throughout the
whole non-coding genome.
Keywords: Indels, Non-coding genome, Variant prioritisation, Support vector machines
Background
The advent of next generation sequencing technologies
has led to a rapid increase in identified genetic variation,
including single nucleotide variants (SNVs), copy number
variants, insertions and deletions (indels), in addition to
larger scale DNA rearrangements. There are now a vast
number of biomedical applications exploiting genomic
sequence data and such data will play a crucial role
in personalised medicine. As a consequence, interpreta-
tion of the functional impact of identified variants is of
increasing importance. This has led to the development
of accurate methods for assessing genomic tolerance and
predictive techniques for discriminating between harmful
(pathogenic) and neutral mutations [1–4].
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In the past, there has been an emphasis on using
sequencing technologies to study human exomes, rather
than full genomes, owing to the reduced costs involved
and a primary focus towards those regions of the genome
deemed to be most functionally relevant. Accordingly,
the vast majority of models for predicting the functional
impact of indels have been restricted to their effect in the
human exome – see e.g. [5–7].
However, the portion of the genome which codes
for proteins accounts for only about 2% of the whole
sequence, and it is becoming increasingly evident that
non–coding portions of the genome play crucial func-
tional roles in human development and disease [8]. For
example, a germline deletion in themicro RNAMIR17HG
leads to microcephaly [9], and a mutation in the pro-
moter region of MIR146A is genetically associated with
lupus [10]. Furthermore, most SNVs identified by genome
wide association studies (GWASs) as correlated with
increased risk of complex disease are located in non–
coding regions [11].
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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Given examples like these, in this paper we focus on
the association between non–coding variants and dis-
ease by developing a model for predicting the functional
impact of indels in non–coding regions of the human
genome. Our method can be seen as a generalisation of
FATHMM [1] for prediction beyond point mutations. A
web–based implementation of FATHMM–indel is avail-
able at indels.biocompute.org.uk.
Methods
Data collection
We developed a machine learning approach to classify the
functional effects of small indels, that is, variants where
the sequence change involves up to 20 base pairs. The
term indel refers to micro insertions/deletions, i.e. muta-
tions that either insert or delete a DNA string to the
wildtype sequence.
Pathogenic non–coding indels were collected from the
CinVar database [12]. From data downloaded on 8th Jan-
uary 2017, we extracted pathogenic mutations (clinical
significance 5) not annotated as somatic. Neutral (likely
benign) non–coding indels were collected from the exome
variant server (EVS) data release ESP6500SIV2 [13]. We
considered variants recorded in individuals of African
ancestry since European and Asian populations have
been subject to bottlenecks which might have resulted
in pathogenic indels with relatively high minor allele fre-
quencies (MAFs) – see e.g. [7]. Thus, to increase the
probability that EVS mutations were truly benign poly-
morphisms, we only selected variants with MAF ≥ 1%
in individuals with African ancestry. In addition to using
database annotations to collect micro insertions/deletions
in non–coding regions, we further exploited Ensembl
GRCh37 (release 85) annotations. By using annotated
coding sequence regions, we were able to verify that all
examples in our data sets did not fall within genomic
regions annotated as protein coding.
Repeats are extremely challenging genomic elements to
sequence as they are characterised by high sequencing
error rates. For example, repeats are strongly affected by
polymerase slippage which can potentially alter the length
of the repetitive sequence mutation [14]. For these rea-
sons, we conservatively filtered all repeats from our data
sets. These steps combined yielded 2 523 pathogenic and
9 783 neutral examples.
FATHMM-indel’s features
We used a variety of data sources which potentially carry
information about an indel’s pathogenic status. Previous
work on SNVs has shown that the best predictive mod-
els exploit information about sequence conservation in
the vicinity of a mutation [2, 15]. Intuitively this makes
sense as we expect that mutations occurring in highly
conserved regions of a genome are more likely to have
deleterious impact compared to those that occur in evo-
lutionary variable regions. However, conservation metrics
used to evaluate SNVs are based on distinct nucleotide
positions within the human genome [1, 16, 17]. Hence, to
study small indels, we must either revise these methods to
produce conservation scores for longer ranges, or devise a
method that uses existing single–nucleotide scores. Here
we adopted the latter approach: to obtain conservation
features for small regions, we treated each insertion or
deletion as a series of mutations in the reference sequence.
All features are described in details in the Additional file 1
(Supplementary Materials).
FATHMM-indel’s model
We used a support vector machine (SVM) [18, 19] as our
binary classifier, as SVMs have produced highly accurate
classifiers for a variety of bioinformatics domains – see,
e.g. [2, 15, 20, 21]. Kernel methods such as SVMs can
easily handle structured data, such as strings and graphs,
which are abundant in bioinformatic applications. Fur-
thermore, support vector machines allow straightforward
integration of heterogeneous biological data.
SVMs use kernel matrices to encode the similarity of
data objects. Kernels have been derived for a number of
different object types, from continuous and discrete vari-
ables, through to graph and sequence data (see e.g. [18]
for an overview). In this work, we used a Gaussian kernel
with precision γ and a “cost” parameter C to lessen the
influence of noise in the data.
SVMs can be used to prioritise variants using Platt
scaling [22]. Given a test instance z, SVMs compute an
“uncalibrated” score
f (z) =
N∑
i=1
αi yi K(xi, z) + b (1)
K represents the kernel matrix encoding the similarity
between data points. The dual parameters αi (Lagrange
multipliers) and b (bias) are learned from training data.
The sum in (1) runs over all training examples xi with class
labels yi = ±1. The score f (z) can be interpreted as a con-
fidence measure since, the larger the modulus | f (z) |, the
greater the confidence of the prediction. f (z) can be con-
verted into a standardised score σ(z) ∈[ 0, 1] by fitting of
a logistic function
σ(z) = 11 + exp(Af (z) + B) (2)
The parameters A and B are learned using maxi-
mum likelihood estimation on training data. Exploiting
this approach, FATHMM–indel can prioritise variants by
returning a score σ for each test mutation. A data point
z is predicted as pathogenic (positive class) if σ(z) ≥ 0.5
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whilst it is predicted as neutral (negative class) other-
wise. Indels with largest scores σ are the most likely to be
pathogenic.
The kernel machine we used is characterised by two
hyperparameters (C, γ ) that need to be optimised in order
to select the best model to validate against currently pub-
lished methods (see Results). One of the most popular
protocols used for model selection is cross validation.
However, it has empirically been shown that cross val-
idation is susceptible of overfitting the model selection
criterion and, consequently, provide an optimistic esti-
mate of generalisation performance [23]. To control again
this potential bias, we performed model selection using a
rigorous nested cross validation (NCV) protocol. NCV is
comprised of two (nested) loops of cross validation where
the inner loop is used for hyperparameter tuning whilst
the outer loop is used for performance assessment (Fig. 1).
The data set is randomly split into ten stratified folds to
ensure that each fold (approximately) contains the same
number of examples for both classes. In each iteration of
the outer loop, nine folds are used to create a tuning set
whilst the remaining fold is used for testing. In the inner
loop, a grid search is performed on the tuning set in order
to select the optimal hyperparameters. A parameter space
is created by setting up possible ranges for the hyperpa-
rameter values and an SVM is trained at each grid position
in such space. The optimal model is selected by imple-
menting ten–fold cross validation and accuracy is used as
performance metric. Lastly, the best model is deployed on
the testing set to assess the performance of the classifier.
This procedure is repeated ten times (the number of strat-
ified folds) and performance is evaluated using sensitivity,
specificity, balanced accuracy, and area under the ROC
curve (AUC).
Results
FATHMM-indel’s performance evaluation
The data collected are substantially imbalanced with
many more neutral than pathogenic instances. Therefore,
in order to annotate a balanced training set, it is neces-
sary to subsample the majority (EVS) class. A data set
can be created by selecting 2 523 pathogenic indels and
randomly drawing 2 523 data points from EVS mutations.
Using such a set, FATHMM–indel’s performance could be
evaluated under nested cross validation.
However, it is crucial to establish whether our model
is robust against subsampling of EVS mutations. Accord-
ingly, we created 50 data sets comprised of 2 523
pathogenic and 2 523 randomly selected neutral indels.
Our model was trained and tested on each set under
nested cross validation. Performance was assessed by
calculating averaged statistics and standard errors (SEs)
across all 50 data sets. FATHMM–indel achieved an aver-
age performance of 89% sensitivity, 89% specificity, 89%
balanced accuracy, and 0.95 AUC (Table 1). The small
standard errors recorded show that our method is robust
against subsampling of EVS indels.
In the next section, we compare our model with pub-
lished methods on benchmark data. The results from
this section indicate FATHMM–indel’s performance is
insensitive to subsampling of the neutral class. There-
fore, to validate our method against state of the art
models, we trained FATHMM–indel using a data set of
2 523 pathogenic and 2 523 randomly sampled neutral
indels. The hyperparameters were set to the values which
recorded highest balanced accuracy under nested cross
validation experiments (C = 10, γ = 0.01).
Validation against publishedmethods
In this section we compare our method with CADD [2]
and GAVIN [24] – two state of the art models for predict-
ing the impact of non–coding indels. Thesemethods allow
comprehensive validation of FATHMM–indel as they are
capable of assessing mutation tolerance throughout the
whole non–coding genome (i.e. they are not restricted to
specific units, e.g. splice sites).
CADD is a prioritisation tool capable of measuring dele-
teriousness by computing “C scores” for genetic variants.
Fig. 1 Nested cross validation. To implement nested cross validation, we split the data set into ten stratified folds. The figure shows one out of ten
NCV loops. For each NCV iteration, an independent testing set (F(10) in the figure) is left out to assess FATHMM-indel’s performance. The remaining
folds (red sets in the figure) are merged to create the tuning set used to learn, under cross validation, the optimal values of the hyperparameters.
Crucially, a different fold is used as testing set in each iteration, fully exploiting all data to evaluate FATHMM-indel’s performance
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Table 1 NCV experiment results. FATHMM-indel’s performance
across 50 data sets created by randomly subsampling the neutral
(EVS) class
Sensitivity (SE) Specificity (SE) Balanced accuracy (SE) AUC (SE)
0.886 (0.005) 0.891 (0.005) 0.889 (0.004) 0.950 (0.003)
The small standard errors (SEs) indicate it is consistent to use one random EVS
sample to train the final model
CADD’s ability to assess the functional impact of muta-
tions was achieved by training an SVM to discriminate
between fixed derived alleles in humans (depleted of dele-
terious variants) and simulated mutations (enriched with
deleterious variants). CADD can also be used to classify
the impact of mutations by selecting an optimal threshold
for C scores. As suggested by CADD’s authors (through
their model web server), all indels with scaled C scores of
at least 15 were predicted as pathogenic.
In addition to predicting the functional class of muta-
tions, FATHMM–indel can also prioritise each variant
by computing a score σ (see Methods). For both CADD
and FATHMM–indel, the higher the score, the higher the
confidence the mutation is functional in disease.
GAVIN is a computational framework that, amongst
others, exploits minor allele frequency data to calibrate
its predictions. GAVIN does not rank mutations but only
classifies the functional impact of a test indel as either
pathogenic or neutral.
To perform an unbiased validation against CADD and
GAVIN, we annotated a balanced benchmark data set
comprised of mutations not used during the training of
any model. Pathogenic indels were obtained from the
human gene mutation database (HGMD) release 2014.v4
[25] whilst neutral instances comprised EVS indels with
MAF ≥ 1%. We restricted our validation examples
to mutations that can be scored by all methods and,
according to our data collection protocol, we did not
consider variants located in repeat regions. Further-
more, we exploited database and Ensembl annotations to
ensure all validation indels were not located in coding
regions. This procedure yielded a benchmark data set with
853 pathogenic (HGMD) indels and 853 neutral (EVS)
indels.
Performance was measured using sensitivity, speci-
ficity, balanced accuracy, and Matthews correlation coef-
ficient (MCC). The results of our empirical validation
on benchmark data are detailed in Table 2. FATHMM–
indel recorded the best performance, achieving a balanced
accuracy of 90% compared to 80% for CADD and 77%
for GAVIN. The substantial improvement in performance
attained by our model is also highlighted by the high
MCC value, showing how FATHMM–indel’s predictions
have the strongest correlation with the true class labels.
Furthermore, the high sensitivity achieved by our model
Table 2 Validation, on benchmark data, against published
methods
Sensitivity Specificity Balanced accuracy MCC
FATHMM-indel 0.905 0.887 0.896 0.793
CADD 0.669 0.934 0.802 0.626
GAVIN 0.611 0.934 0.773 0.576
demonstrates FATHMM–indel’s ability to identify truly
pathogenic variants. This underlines the potential prac-
tical usefulness of our model in, for example, clinical
settings where it is crucial not to erroneously categorise
pathogenic mutations. Both CADD and GAVIN manifest
a bias towards assessing the impact of validation indels
as neutral. This has allowed CADD and GAVIN to reach
high specificities but very low sensitivities due to the high
number of false negatives (FNs). GAVIN recorded the
highest value of false negatives (FN = 332, 39% of bench-
mark pathogenic indels), followed by CADD (FN = 282),
whereas FATHMM–indel is characterised by the lowest
number FN = 81 (9% of benchmark pathogenic indels).
The somewhat lower specificity of our model is a con-
sequence of a slightly higher false positive rate as 11%
of benchmark neutral indels were erroneously predicted
as pathogenic by FATHMM–indel, whilst 7% of valida-
tion neutral indels were miscategorised by CADD and
GAVIN.
Since both CADD and FATHMM–indel score variants
for prioritisation, it is possible to further compare these
models’ performance by means of ROC curves and cor-
responding AUC statistics. For binary classification, a
ROC curve displays the true positive rate (sensitivity) as
a function of the true negative rate (1 − specificity). The
points of the curve are computed by varying the deci-
sion threshold from the most positive (pathogenic) data
point to the most negative (neutral) one. This allows
us to comprehensively validate these models and anal-
yse their performance over the range of possible clas-
sification thresholds. The area under the ROC curve,
known as AUC, measures the ranking quality of a clas-
sification hypothesis [26]. A perfect classifier would have
unit AUC whereas random guessing would achieve an
AUC of 0.5. The ROC curves of FATHMM–indel and
CADD, obtained using the benchmark data set, are visu-
alised in Fig. 2. FATHMM–indel was the best performing
method achieving an AUC of 0.956 compared to 0.921
of CADD.
In our validation experiments on benchmark data,
FATHMM–indel has shown significant performance
improvements over published models. This also validates
the ability of FATHMM–indel to generalise to other data
sets and establish FATHMM–indel scores as informative
metrics for variant prioritisation.
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Fig. 2 Empirical ROC curves for FATHMM-indel and CADD. Performance comparison, on benchmark data, between FATHMM-indel and CADD. ROC
curves display sensitivities and false positive rates at all possible cutoff levels. Therefore, they can be used to assess the performance of a model
independently of the decision threshold
FATHMM-indel for population genetics
To further assess the validity of our approach, we collected
non–coding indels from the latest data release (phase 3)
of the 1 000 genomes (1KG) project [27]. Amongst its
principal goals, the 1KG project aims at analysing the
distribution of common and rare mutations in order to
provide a broad representation of human genetic varia-
tion. In the project’s final phase (phase 3), 2 504 genomes
were reconstructed from apparently healthy individuals
which are stratified into the 5 “continental” populations
of East Asia (EAS), South Asia (SAS), Europe (EUR),
Africa (AFR), and America (AMR). The 1KG data set also
annotates the allele frequency (AF) for each continental
population as well as the allele frequency for the global
(GLB) sample. This allows to comprehensively analyse
private (population specific) alleles and shared variants.
By collecting small variants not located in repetitive
regions, we were able to score 1,466,000 non–coding
indels from 1KG data. FATHMM–indel classified the vast
majority of mutations as neutral, achieving an accuracy of
96%. This represents additional evidence supporting the
informativeness of FATHMM–indel’s scores for assessing
genomic tolerance of non–coding variants.
Exploiting AF data, it is possible to analyse how evo-
lutionary pressures are acting outside the exome by
considering the frequency spectrum of indels predicted
as pathogenic. We examined the distribution of 1KG
indels by binning variants into three categories (Fig. 3).
Rare indels have AF < 0.01, low frequency indels have
AF ∈ [ 0.01, 0.05], whereas common indels have AF >
0.05. Purifying selection removes disadvantageous alleles
by reducing their frequency in a population. Therefore,
common indels are less likely to be pathogenic than rare
indels. We observed this phenomenon across all conti-
nental and global populations where the highest percent-
ages of pathogenic indels are rare. Within the continental
populations, AMR recorded the highest ratio (55%), fol-
lowed by EUR (48%), AFR (47%), SAS (47%), and EAS
(45%). This trend is even more prominent in the global
population where the vast majority (70%) of pathogenic
indels are rare. Non–rare variants shared across popula-
tions are typically older than non–rare private mutations
and, therefore, less likely to be pathogenic.
Furthermore, by looking at common indels, we can
analyse how bottlenecks have differentially effected pop-
ulations. A drastic reduction in population size followed
by a rapid growth enables deleterious variants to accu-
mulate at high frequency [28]. European and Asian have
been subjects of severe bottlenecks [27, 28] and, as can be
seen in Fig. 3, these populations harbour higher ratios of
pathogenic indels which are common. EAS has the high-
est percentage (41%) of disadvantageous common indels,
followed by SAS (37%) and EUR (37%). Conversely, the
African population is characterised by a much smaller
ratio of pathogenic and common indels (29%). Interest-
ingly, at least for the indels that we were able to score,
the distribution of AMR indels is much more similar
to the AFR frequency spectrum as, for instance, only
28% of pathogenic indels are common in the American
population.
Discussion
We presented FATHMM–indel, an integrative method
to assess mutation tolerance throughout the whole
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Fig. 3 Frequency spectrum for 1 KG indels predicted as pathogenic. Comparison between non-coding variants across populations and stratified
according to allele frequency (AF<1% for rare indels and AF>5% for common indels)
non–coding genome.When validated on benchmark data,
FATHMM–indel outperformed CADD and GAVIN, state
of the art models for predicting the functional impact
of non–coding variants. In addition to predicting the
functional class (pathogenic or neutral) of an indel, our
method is capable of prioritising variants by computing a
standardised score (σ ) for each test mutation. This intro-
duces an additional level of flexibility by enabling the
implementation of cautious classification to only consider
predictions with highest confidence. Given the distribu-
tion of FATHMM–indel scores over validation indels, it
is possible to cautiously classify our benchmark data set.
For example, one can predict an indel with a score bigger
than the 80th percentile (0.967) as pathogenic, whilst
a mutation with a σ smaller than the 20th percentile
(0.034) as neutral. This restricts the number of variants
classified to 40% of all benchmark indels but, crucially,
allows FATHMM–indel to achieve almost perfect perfor-
mance with a balanced accuracy of 98%. The interplay
between balanced accuracy and the proportion of bench-
mark indels cautiously classified is comprehensively visu-
alised in Fig. 4. Cautious classification could be extremely
useful in, for instance, medical genetics research where,
from a “pool” of putative variants, one is interested in
selecting only a small subset of candidate mutations for
experimental validation.
Fig. 4 Cautious classification of benchmark indels. Balanced accuracy, over validation data, as a function of the decision threshold. By selecting only
predictions with highest confidence, FATHMM-indel is capable of achieving almost perfect classification
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Given current estimates quantifying that at least 5%
of the human genome is evolutionary constrained [29],
it is crucial to deepen our understanding of how selec-
tive pressures are acting on non–coding elements. The
distribution and evolution of deleterious alleles are fun-
damental in elucidating the genetic architecture of human
disease. In this work, we have also shown how FATHMM–
indel can be valuable to discover and analyse differences
in non–coding mutation loads across populations.
Our model is available through a web server at
indels.biocompute.org.uk. By uploading a file in (simpli-
fied) VCF, users can submit batches of indels. For a large
submission of 10,000 variants, the web server returns
FATHMM–indel scores within 30 min (on average).
FATHMM–indel was developed by harvesting knowl-
edge from multiple genomic sources and performing
integration at the level of data, where all features are
annotated in one data set and similarities between exam-
ples are encoded in a unique kernel. As an avenue for
future research, it would be interesting to investigate
whether it is possible to further boost FATHMM–indel’s
performance by implementing multiple kernel learning
(MKL). Within an MKL approach, multiple data sources
are arranged into several feature groups, each with its
own kernel matrix – see, e.g [30]. Further data sources
are available thanks to the efforts of projects like the
encyclopedia of DNA elements (ENCODE) consortium
[31], which also aims at mapping functional and regu-
latory elements located outside protein coding regions.
For example, it would be possible to annotate an addi-
tional feature group from transcription factor binding
sites data, which have recorded excellent predictive power
in assessing genomic tolerance of non–coding SNVs [15].
Currently, as a consequence of our data collection pro-
tocol, FATHMM–indel is unable to accurately prioritise
non–coding variants located in repetitive regions. Before
all repeats were filtered from our training data, 1% of
pathogenic indels were repeats whilst 21% of neutral
indels were located in repetitive elements. Annotating a
training set by random sampling of repetitive sequences
would lead to over representation of repeats within the
neutral class and, consequently, result in the introduc-
tion of a potential confounding factor. Hence, extending
FATHMM–indel’s capabilities to prioritise repeats war-
rants further and careful analyses that we leave to future
work.
Conclusions
We developed FATHMM–indel, an integrative computa-
tional model for predicting indel pathogenicity. Although
the vast majority of genetic alterations lie outside the
exome, there is a lack of methods specifically designed to
predict the impact of indels throughout the whole non–
coding genome.We developed ourmodel to fill in this gap,
to aid in predicting the biological consequences of non–
coding variants. We envisage FATHMM–indel as a useful
annotation tool that could be used, for example, to priori-
tise causative variants, like those identified in GWASs, for
downstream studies to analyse the phenotypic impact of
non–coding indels.
Additional file
Additional file 1: Supplementary Materials. In this PDF file, we report a
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